Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

April 7, 2017

Primary Completion Date

April 7, 2021

Study Completion Date

April 7, 2021

Conditions
Rheumatoid Arthritis Interstitial Lung Disease
Interventions
DRUG

Pirfenidone

Pirfenidone three times daily (2403 mg) for 52 weeks

DRUG

Placebo

Placebo three times daily for 52 weeks

Trial Locations (33)

2050

The Prince Charles Hospital, Camperdown

3004

Melbourne Alfred Hospital, Melbourne

4032

Royal Brompton, Brisbane

10065

Weill Cornell Medicine, New York

21224

John Hopkins Medicine, Baltimore

33136

University of Miami, Miami

35294

University of Alabama Site at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

70112

Tulane Medical Center, New Orleans

80206

National Jewish Health, Denver

84132

University of Utah Health Care, Salt Lake City

94143

University of California San Francisco, San Francisco

98195

University of Washington, Seattle

02115

Brigham and Women's Hospital, Boston

NSW 2050

Royal Prince Alfred Hospital, Camperdown

T3M 1M4

University of Calgary Cummings School of Medicine, Calgary

V6Z1Y6

St. Paul's Hospital - Providence Health Care, Vancouver

L8N 4A6

St. Joseph's Healthcare, Hamilton

M5G 2C4

Toronto General Hospital, Toronto

BS10 5NB

North Bristol NHS Trust Headquarters, Southmead Hospital, Bristol

CB23 3RE

Papworth Hospital NHS Foundation Trust, Cambridge

EX2 5DW

Royal Devon and Exeter NHS Foundation, Exeter

LS9 7TF

Leeds Teaching Hospitals NHS Trust, Leeds

LE3 9QP

University Hospitals of Leicester NHS Foundation Trust, Leicester

L9 7AL

Aintree University Hospitals NHS Foundation Trust, Liverpool

SW3 6NP

Royal Brompton and Harefield NHS Foundation Trust, London

M23 9LT

Manchester University NHS Foundation Trust (South) Wythenshawe Hospita, Manchester

NE1 4LP

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

NR4 7UY

Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich

OX3 7LE

Oxford University Hospitals NHS Foundation Trust, Oxford

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southhampton

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT02808871 - Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1) | Biotech Hunter | Biotech Hunter